COMMUNIQUÉS West-GlobeNewswire

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
06/05/2026
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the [...]
Annexon to Present at the Bank of America Securities Health Care Conference 2026
06/05/2026
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
06/05/2026
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, [...]
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
06/05/2026
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology [...]
Aktis Oncology to Present at the BofA Securities Health Care Conference
06/05/2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large [...]
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
06/05/2026
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - [...]
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
06/05/2026
200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a [...]
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
06/05/2026
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer Bria-BRES+ is BriaCell’s next generation personalized immunotherapy [...]
Recursion Reports First Quarter Financial Results and Provides Business Update
06/05/2026
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, dose- [...]
Cronos Expands Pre-Roll Portfolio with Spinach STIX®
06/05/2026
TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, announced today that Spinach STIX ® , its latest innovation in its popular line- [...]
Medline Reports First Quarter 2026 Results
06/05/2026
Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance range to 8.5% to 9.5 [...]
Immusoft to Present Data Highlighting Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial at ASGCT 2026
06/05/2026
SAN FRANCISCO, May 06, 2026 (GLOBE NEWSWIRE) -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that Scott McIvor, Chief Development Officer at Immusoft, [...]
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
06/05/2026
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its [...]
Glass House Brands Announces Application for DEA Registration of Certain Medical Operations
06/05/2026
LONG BEACH, Calif. and TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) today announced that it has submitted [...]
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
06/05/2026
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Bioventus Reports First Quarter Financial Results
06/05/2026
Q1 reported revenue of $132.1 million increased 7% First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share Non-GAAP earnings* of $0.15 per diluted share [...]
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
06/05/2026
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Valneva publiera ses résultats financiers consolidés du premier trimestre le 13 mai 2026
06/05/2026
Lyon (France), le 6 mai 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers du premier trimestre le mercredi 13 [...]
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
06/05/2026
GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will [...]

Pages